Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$8.12 USD
-0.18 (-2.17%)
Updated May 3, 2024 04:00 PM ET
After-Market: $8.11 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IRWD 8.12 -0.18(-2.17%)
Will IRWD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRWD
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
Other News for IRWD
Ironwood Pharmaceuticals: A Strong Buy on Solid Financials and Promising Drug Developments
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)